Lines are open Mon-Fri 08:00 - 18:00
PharmaGenoma, Inc., a pharmacogenomics research and development innovator, and its subsidiary HairDX, LLC, has today made known that it has received the approval of the institutional review board (IRB) to commence clinical trials of a genetically tailored therapy for female baldness (Androgenetic Alopecia).
Andy Goren, Chairman and Chief Strategist of PharmaGenoma, Inc and HairDX, LLC, has reiterated that the company's ultimate objective is to transform the field of dermatology through an innovative approach to genetically tailored treatments for familiar skin disorders.
For this purpose, HairDX is set to begin enlisting post menopausal women as patients for this study. Women who meet the requirements for the study will be made to undergo genetic screening. Moreover, if a woman is found to show evidence of a particular genetic variation in her 'Androgen Receptor' gene, she will receive a drug that may have the potential to re-grow her hair. This trial is projected to start in early fall.
As opined by Antonella Tosti, MD, Professor of Dermatology at the University of Bologna in Italy, that, thus far no systemic drug treatment is available for Female Androgenetic Alopecia. The perceived drug trial by HairDX may therefore usher a new era in the treatment of Female Androgenetic Alopecia.
Head of the Crown Human Genome Center at the Department of Molecular Genetics, Weizmann Institute of Science, Professor Doron Lancet, has stated that dermatologists though often prescribe hair loss treatment drugs to women, only a fraction of women respond to those therapies. Should this clinical trial prove successful, dermatologists will be in a position to tailor individual treatments for hair loss based on a woman's genetic makeup.
Since the early part of 2008, HairDX has become the first company to market genetic tests through physicians that predict an individual's risk for male or female pattern androgenetic alopecia.
For the purpose, HairDX uses a CLIA certified laboratory (Clinical Laboratory Improvement Amendments) to perform the genetic analysis. This has helped HairDX offer physicians a powerful screening test for androgenetic alopecia before any visible signs of hair loss are seen. The test results are expected to assist physicians in choosing a course of action that will play a major role in maintaining an individual's hair count.